Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lieberman, J.
Right arrow Articles by Mishkin, F. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lieberman, J.
Right arrow Articles by Mishkin, F. S.

Chest, Vol 84, 522-528, Copyright © 1983 by American College of Chest Physicians

ARTICLES

Clinical correlations of serum angiotensin-converting enzyme (ACE) in sarcoidosis. A longitudinal study of serum ACE, 67gallium scans, chest roentgenograms, and pulmonary function

J Lieberman, LA Schleissner, A Nosal, A Sastre and FS Mishkin

Thirty-one patients with biopsy-confirmed sarcoidosis were studied for two to four years to compare serum angiotensin-converting enzyme (ACE) levels to clinical status, 67gallium scans, chest x-ray films, and pulmonary function tests (PFTs). Serum ACE levels and changes in ACE level correlated best with the clinical status of patients and their gallium scans (p less than 0.0005), and less with their chest x-ray films (p = 0.012) or PFTs (p = 0.007). The gallium scan was especially useful for localizing areas of disease involvement. Serial measurements of serum ACE were found to be a sensitive means for following the clinical course of patients with sarcoidosis and at times for predicting clinical relapse or improvement.


This article has been cited by other articles:


Home page
 ChestHome page
J. C. Grutters, J.-M. Fellrath, L. Mulder, R. Janssen, J. M. M. van den Bosch, and H. van Velzen-Blad
Serum Soluble Interleukin-2 Receptor Measurement in Patients With Sarcoidosis: A Clinical Evaluation
Chest, July 1, 2003; 124(1): 186 - 195.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. W. ZIEGENHAGEN, U. K. BENNER, G. ZISSEL, P. ZABEL, M. SCHLAAK, and J. MÜLLER-QUERNHEIM
Sarcoidosis: TNF-alpha Release from Alveolar Macrophages and Serum Level of sIL-2R Are Prognostic Markers
Am. J. Respir. Crit. Care Med., November 1, 1997; 156(5): 1586 - 1592.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1983 by the American College of Chest Physicians.